Transcriptional activation of cyclooxygenase-2 by tumor suppressor p53 requires nuclear factor-kappaB

被引:45
作者
Benoit, V.
de Moraes, E.
Dar, N. A.
Taranchon, E.
Bours, V.
Hautefeuille, A.
Taniere, P.
Chariot, A.
Scoazec, J-Y
Gallo, C. V. de Moura
Merville, M-P
Hainaut, P.
机构
[1] Int Agcy Res Canc, Grp Mol Carcinogenesis, F-69372 Lyon, France
[2] Univ Liege, Lab Med Chem & Human Genet, Ctr Biomed Integrated Genoproteom, Liege, Belgium
[3] Hop Edouard Herriot, Dept Pathol, Lyon, France
[4] State Uni Rio de Janeiro, Dept Cellular Biol & Genet, Rio De Janeiro, Brazil
关键词
p53; NF-kappaB; cyclooxygenase-2 esophageal cancer; Barrett's metaplasia;
D O I
10.1038/sj.onc.1209579
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Overexpression of cyclooxygenase-2 (Cox-2) is thought to exert antiapoptotic effects in cancer. Here we show that the tumor suppressor p53 upregulated Cox-2 in esophageal and colon cancer cell lines by inducing the binding of nuclear factor-kappaB (NF-kappaB) to its response element in the COX-2 promoter. Inhibition of NF-kappaB prevented p53 induction of Cox-2 expression. Cooperation between p53 and NF-kappaB was required for activation of COX-2 promoter in response to daunomycin, a DNA-damaging agent. Pharmacological inhibition of Cox-2 enhanced apoptosis in response to daunomycin, in particular in cells containing active p53. In esophageal cancer, there was a correlation between Cox-2 expression and wild-type TP53 in Barrett's esophagus (BE) and in adenocarcinoma, but not in squamous cell carcinoma (P < 0.01). These results suggest that p53 and NF-kappaB cooperate in upregulating Cox-2 expression, promoting cell survival in inflammatory precursor lesions such as BE.
引用
收藏
页码:5708 / 5718
页数:11
相关论文
共 57 条
[1]  
Barnas C, 1997, INT J CANCER, V71, P79, DOI 10.1002/(SICI)1097-0215(19970328)71:1<79::AID-IJC14>3.0.CO
[2]  
2-4
[3]   Acute ablation of survivin uncovers p53-dependent mitotic checkpoint functions and control of mitochondrial apoptosis [J].
Beltrami, E ;
Plescia, J ;
Wilkinson, JC ;
Duckett, CS ;
Altieri, DC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (03) :2077-2084
[4]   Additive effect between NF-κB subunits and p53 protein for transcriptional activation of human p53 promoter [J].
Benoit, V ;
Hellin, AC ;
Huygen, S ;
Gielen, J ;
Bours, V ;
Merville, MP .
ONCOGENE, 2000, 19 (41) :4787-4794
[5]  
Bentires-Alj M, 1999, CANCER RES, V59, P811
[6]   Inhibition of the NF-κB transcription factor increases Bax expression in cancer cell lines [J].
Bentires-Alj, M ;
Dejardin, E ;
Viatour, P ;
Van Lint, C ;
Froesch, B ;
Reed, JC ;
Merville, MP ;
Bours, V .
ONCOGENE, 2001, 20 (22) :2805-2813
[7]   NF-κB and chemoresistance:: could NF-κB be an antitumor target? [J].
Bentires-Alj, M ;
Merville, MP ;
Bours, V .
DRUG RESISTANCE UPDATES, 1999, 2 (04) :274-276
[8]   Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid [J].
Birkenkamp-Demtroder, K ;
Olesen, SH ;
Sorensen, FB ;
Laurberg, S ;
Laiho, P ;
Aaltonen, LA ;
Orntoft, TF .
GUT, 2005, 54 (03) :374-384
[9]   p53 induces NF-κB activation by an IκB kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1 [J].
Bohuslav, J ;
Chen, LF ;
Kwon, H ;
Mu, YJ ;
Greene, WC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (25) :26115-26125
[10]   Comparison of cyclooxygenase 2 expression in adenocarcinomas of the gastric cardia and distal oesophagus [J].
Buskens, CJ ;
Sivula, A ;
van Rees, BP ;
Haglund, C ;
Offerhaus, GJA ;
van Lanschot, JJB ;
Ristimäki, A .
GUT, 2003, 52 (12) :1678-1683